Add to ORKGIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastase
AbstractBackground/AimSevere bone pain is experienced by 60–80% of patients with metastatic bone dis...
Ibandronate is a potent bisphosphonate which has been most thoroughly assessed in benign bone diseas...
The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with...
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with place...
Use of ibandronate in the prevention of skeletal events in metastatic breast cance
Background: This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate...
Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidi...
Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple my...
Purpose<p></p> This phase II trial evaluated the efficacy and safety of loading-dose I....
BACKGROUND: Bisphosphonates are routinely used in the treatment of metastatic bone disease from brea...
Background/Aim: Severe bone pain is experienced by 60–80% of patients with metastatic bone disease, ...
Background: We report the first results of a randomized trial assessing a new oral aminobisphosphona...
PubMed ID: 22868504Background: The aim of this study was to determine the efficacy and safety of loa...
Philip SambrookUniversity of Sydney, SydneyAbstract: Osteoporosis is a chronic condition that genera...
Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of...
AbstractBackground/AimSevere bone pain is experienced by 60–80% of patients with metastatic bone dis...
Ibandronate is a potent bisphosphonate which has been most thoroughly assessed in benign bone diseas...
The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with...
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with place...
Use of ibandronate in the prevention of skeletal events in metastatic breast cance
Background: This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate...
Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidi...
Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple my...
Purpose<p></p> This phase II trial evaluated the efficacy and safety of loading-dose I....
BACKGROUND: Bisphosphonates are routinely used in the treatment of metastatic bone disease from brea...
Background/Aim: Severe bone pain is experienced by 60–80% of patients with metastatic bone disease, ...
Background: We report the first results of a randomized trial assessing a new oral aminobisphosphona...
PubMed ID: 22868504Background: The aim of this study was to determine the efficacy and safety of loa...
Philip SambrookUniversity of Sydney, SydneyAbstract: Osteoporosis is a chronic condition that genera...
Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of...
AbstractBackground/AimSevere bone pain is experienced by 60–80% of patients with metastatic bone dis...
Ibandronate is a potent bisphosphonate which has been most thoroughly assessed in benign bone diseas...
The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with...